Pharmacology and hypnotic efficacy of triazolam

Pharmacotherapy
T RothF Zorick

Abstract

Triazolam is a new triazolobenzodiazepine drug that is indicated for the treatment of insomnia. The usual adult dosage is 0.25 to 0.5 mg; for geriatric patients a dose of 0.125 to 0.25 mg is recommended. Triazolam is readily absorbed and quickly eliminated with a half-life of 2-5 hours, making it the shortest acting benzodiazepine available in the United States. Sleep laboratory and non-laboratory clinical trials found triazolam 0.25 and 0.5 mg effective in inducing and maintaining sleep. It remained effective in laboratory studies of up to one month duration and non-laboratory studies of up to six months duration when the drug was administered nightly. On discontinuation disturbed sleep for one or two nights was observed in some studies. Triazolam impairs performance for several hours after administration. However, unlike benzodiazepines with long-acting metabolites, triazolam is relatively free of daytime residual effects, which is attributable to its short half-life. Overall, triazolam is an effective and safe compound for the symptomatic treatment of insomnia complaints.

References

Jan 1, 1976·The Journal of International Medical Research·P Lomen, O I Linet
Jan 1, 1976·The Journal of International Medical Research·T RothT Lutz
Jan 1, 1976·The Journal of International Medical Research·L F FabreR T Harris
May 1, 1978·Journal of Clinical Pharmacology·M Leibowitz, A Sunshine
Jan 1, 1978·The Journal of International Medical Research·A J Bowen
Jan 1, 1978·The Journal of International Medical Research·K K Okawa, G S Allens
Jan 1, 1979·British Journal of Clinical Pharmacology·H J Schwarz
Jan 1, 1979·British Journal of Clinical Pharmacology·D D Breimer
Sep 8, 1979·Lancet·C van der Kroef
Jan 1, 1975·Psychopharmacologia·G W VogelK Sexton
Jun 1, 1975·Archives of General Psychiatry·G W Vogel
Apr 1, 1977·Journal of Clinical Pharmacology·A KalesM B Scharf
Sep 15, 1978·Science·A KalesJ D Kales
Dec 1, 1973·Journal of Pharmaceutical Sciences·S A KaplanL Weissman
Feb 1, 1980·British Journal of Clinical Pharmacology·A N Nicholson, B M Stone
Apr 25, 1980·Science·K M HartseF Zorick
Jan 1, 1980·The Journal of International Medical Research·V PegramP Linton
Jan 1, 1980·Psychopharmacology·C OguraW M Wardell
Jan 1, 1980·The Journal of International Medical Research·P M PiccioneT Roth
Jan 1, 1981·Clinical Pharmacology and Therapeutics·F S EbertsR W Vliek
Mar 27, 1982·British Medical Journal·K Morgan, I Oswald
Jan 1, 1982·Psychopharmacology·C L Spinweber, L C Johnson
Jan 1, 1981·British Journal of Clinical Pharmacology·D J GreenblattJ S Harmatz

Citations

Jun 13, 1991·The New England Journal of Medicine·D J GreenblattR I Shader
Mar 1, 1988·Journal of Clinical Pharmacology·H FriedmanR I Shader
Dec 1, 1986·British Journal of Clinical Pharmacology·H FriedmanR I Shader
Dec 1, 1984·Drug Intelligence & Clinical Pharmacy·W A Parker, R A MacLachlan
Jan 1, 1986·Acta Psychiatrica Scandinavica. Supplementum·K Rickels
Jan 1, 1988·Psychological Medicine. Monograph Supplement·A HiggittM Lader
Jan 18, 2006·Journal of Clinical Psychopharmacology·D J Greenblatt
Jun 1, 1990·Journal of Clinical Pharmacology·M MamelakV Price
Jan 1, 1983·British Journal of Clinical Pharmacology·M MamelakV Price
Jun 1, 1987·British Journal of Clinical Pharmacology·H R OchsE S Burstein
Sep 17, 1987·The New England Journal of Medicine·D J GreenblattR I Shader
Dec 12, 1991·The New England Journal of Medicine
May 30, 2007·Clinical Drug Investigation·Mario Giovanni TerzanoMembers of the Advisory Board
Apr 1, 1986·Drug Intelligence & Clinical Pharmacy·C R SoldatosC N Stefanis
Sep 1, 1996·Psychopharmacology·T RoehrsT Roth
Jan 1, 1990·Journal of Psychoactive Drugs·V L Martin

Related Concepts

Metazoa
Metabolic Biotransformation
Drug Evaluation
Half-Life
Transient Insomnia
Lethal Dose 50
Sleep, Slow-Wave
Sleep Stages
Anti-Anxiety Effect
Trilam

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Lipidomics & Rhinovirus Infection

Lipidomics can be used to examine the lipid species involved with pathogenic conditions, such as viral associated inflammation. Discovered the latest research on Lipidomics & Rhinovirus Infection.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Torsion Dystonia

Torsion dystonia is a movement disorder characterized by loss of control of voluntary movements appearing as sustained muscle contractions and/or abnormal postures. Here is the latest research.

Generating Insulin-Secreting Cells

Reprogramming cells or using induced pluripotent stem cells to generate insulin-secreting cells has significant therapeutic implications for diabetics. Here is the latest research on generation of insulin-secreting cells.

Central Pontine Myelinolysis

Central Pontine Myelinolysis is a neurologic disorder caused most frequently by rapid correction of hyponatremia and is characterized by demyelination that affects the central portion of the base of the pons. Here is the latest research on this disease.

Epigenome Editing

Epigenome editing is the directed modification of epigenetic marks on chromatin at specified loci. This tool has many applications in research as well as in the clinic. Find the latest research on epigenome editing here.